Avacincaptad pegol
Based on 1 Customer Validation
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 92.19%
- No. CAS: 1613641-69-2
- Peso molecular:52603 (Approximately)
-
Almacenamiento:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Actividad biológica
|
C5 |
Avacincaptad pegol exerts its complement inhibitory activity by specifically binding to complement component C5, inhibiting its cleavage into pro-inflammatory C5a and C5b, which forms the membrane attack complex (MAC), thus blocking the terminal steps of the complement cascade[1].
Avacincaptad pegol can inhibit the damage to retinal pigment epithelial (RPE) cells caused by the complement activation product C5b-9, reduce lysosomal overload and the release of pro-inflammatory factors, maintain the stability of RPE cell function, and is associated with the improvement of pathological processes related to age-related macular degeneration (AMD)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus macaques (Macaca fascicularis) (male, 2.9-6.6 kg, 3.4-5.0 years old) sodium iodate-induced dry age-related macular degeneration (AMD) with geographic atrophy (GA) model[2]
-
Dosage:Initial 1.5 mg/eye ubsequent doses adjusted to 1 mg/eye (phosphate-buffered saline)
-
Administration:16 weeks
-
Result:The mean GA area in Avacincaptad pegol-treated eyes (11.4 ± 4.0 mm2) was reduced by approximately 36% compared with vehicle-treated eyes (18.9 ± 6.6 mm2), though the difference was not statistically significant.
Avacincaptad pegol did not alter the thinning of total retinal thickness or central macular thickness induced by sodium iodate. No choroidal neovascularization (CNV) was observed in either the treatment or vehicle group.
Choroidal capillary (CC) leakage under or around the macula was detected in both groups, with no statistically significant difference in the incidence of CC leakage between the two groups.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1613641-69-2
-
Appearance Solid
-
Peso molecular 52603 (Approximately)
-
Color White to off-white
-
SMILES
[Avacincaptad pegol]
-
Synonyms
Izervay
-
Sequence
Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, 5′-ether with RNA ((2′-deoxy-2′-fluoro)C-Gm-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-G-(2′-deoxy-2′-fluoro)C-Gm-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-Am-Gm-Gm-(2′-deoxy-2′-fluoro)C-G-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-A-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)C-Gm-(3′→3′)-dT) 5′-[6-[[(2,3-dihydroxypropoxy)carbonyl]amino]hexyl hydrogen phosphate] (2:1)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (1518 KB)
Referencias
[1]. Danzig CJ, et al. C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review. Immunotherapy. 2024;16(12):779-790. [Content Brief]
[2]. Fujii R, et al. Intravitreal Administration of Avacincaptad Pegol in a Nonhuman Primate Model of Dry Age-Related Macular Degeneration. Pharmacol Res Perspect. 2025 Feb;13(1):e70052. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)